TargetMol

Gypenoside L

Product Code:
 
TAR-TN1721
Supplier:
 
TargetMol
Regulatory Status:
 
RUO
Shipping:
 
cool pack
Storage:
 
-20℃
1 / 1
❮❯

No additional charges, what you see is what you pay! *

CodeSizePrice
TAR-TN1721-1mg1mg£173.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-TN1721-5mg5mg£321.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-TN1721-10mg10mg£389.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
Prices exclude any Taxes / VAT
How to order with us   Contact us
Stay in control of your spending. These prices have no additional charges, not even shipping!
* Rare exceptions are clearly labelled (only 0.14% of items!).
Multibuy discounts available! Contact us to find what you can save.
This product comes from: United States.
Typical lead time: 10-14 working days.
Contact us for more accurate information.
  • Further Information
  • Documents
  • References
  • Show All

Further Information

Bioactivity:
Gypenoside L inhibits autophagic flux and induces cell death in human esophageal cancer cells through endoplasm reticulum stress-mediated Ca2+ release. It also inhibit non-small cell lung carcinoma A549 cell inhibitory activity.
CAS:
94987-09-4
Formula:
C42H72O14
Molecular Weight:
801.024
Pathway:
Membrane transporter/Ion channel; Immunology/Inflammation; Metabolism; MAPK; NF-κb
Purity:
0.9942
SMILES:
CC(C)=CCC[C@](C)(O)[C@H]1CC[C@]2(C)[C@@H]1[C@H](O)C[C@@H]1[C@@]3(C)C[C@@H](O)[C@H](O[C@@H]4O[C@H](CO)[C@@H](O)[C@H](O)[C@H]4O[C@@H]4O[C@H](CO)[C@@H](O)[C@H](O)[C@H]4O)C(C)(C)[C@@H]3CC[C@@]21C
Target:
ERK; p38 MAPK; Calcium Channel; NF-κB; ROS

References

Jingxin Ma , Xiaopeng Hu , Chenghui Liao,et al. Gypenoside L Inhibits Proliferation of Liver and Esophageal Cancer Cells by Inducing Senescence.[J]. Molecules (Basel, Switzerland), 2019. Dammarane-type saponins from heat-processed Gynostemma pentaphyllum show fortified activity against A549 cells. Archives of Pharmacal Research, 2013, 36(7):874-879.